These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Author: Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH.
    Journal: Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966.
    Abstract:
    BACKGROUND: Patients with advanced esophageal cancer are frequently not indicated for intensive chemotherapy due to aero-digestive tract complications. In order to improve the therapeutic index of systemic chemotherapy for these patients, we designed a weekly MP-HDFL protocol, which took advantage of the low toxicity of the infusional dosing schedule for cisplatin and 5-fluorouracil (5-FU), and double biochemical modulation of 5-FU by methotrexate and leucovorin. PATIENTS AND METHODS: Between April 1997 and April 2001, a total of 26 patients (M:F = 22:4) with a median age of 59.5 (range: 43-81) years were enrolled into this phase II clinical trial prospectively. There were 12 patients with de novo metastatic disease, 13 with recurrent disease (including 7 relapsed from previous concurrent chemoradiotherapy incorporating cisplatin and 5-FU), and one with locally advanced disease. The weekly MP-HDFL protocol was composed of methotrexate 40 mg/m2, i.v., on days 1, 8, 15; cisplatin 35 mg/m2, 24-hour IVF, on days 2, 9, 16; and 5-FU 2,600 mg/m2 and leucovorin 300 mg/m2, 24-hour IVF, on days 2, 9, 16; repeated every 28 days. RESULTS: A total of 97 courses were given with an average of 3.7 courses per patient (range: 1-19). All of the patients were assessable for evaluation of toxicity. Grades 3/4 leukopenia and thrombocytopenia were noted in 13 (14%) and 17 (18%) of the treatment courses, respectively. There were 3 episodes of febrile neutropenia in 2 patients, and lethal sepsis in one patient. The Grades 3/4 non-hematological toxicities were infrequent. Among 25 patients with recurrent or metastatic disease, 7 had partial response and 12 had stable disease. The response rate for the intent- to treat group was 28% (95% C.I.:12%-49%). The median survival was 5 months (range: 1-28 months). CONCLUSION: Weekly MP-HDFL combination chemotherapy is associated with mild and acceptable toxicity, and has modest palliative activity in a portion of advanced esophageal cancer patients. However, a more active and better tolerated anticancer drug combination is needed to improve the outcome of these patients.
    [Abstract] [Full Text] [Related] [New Search]